Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

News

$Enveric Biosciences(ENVB.US)$ Cannabinoids With Chemotherapy For Breast Cancer: Psychedelics Biotech Inks $61M License Deal For Patented Methods
Benzinga· 6 mins ago
Enveric Biosciences (NASDAQ:ENVB), a Nasdaq-listed psychedelics biotech firm, has entered into a non-binding term sheet with an undisclosed biotech company (licensee) for an exclusive license to two patented methods aimed at treating breast cancer and other cancers. These methods utilize cannabinoids in combination with chemotherapeutic drugs.
As per the agreement, the licensee will obtain an exclusive, global license to these methods, along with any devices and drugs developed to implement them. The licensee will also take on all future preclinical and clinical development responsibilities on a royalty-bearing basis for both human and animal pharmaceutical applications.
Subject to certain conditions, the licensee will compensate Enveric with a License Execution Fee and provide development and sales milestones totaling up to $61 million. Additionally, Enveric will receive royalties ranging from 2.5% to 10% on all future sales. The licensee also retains a cash buyout option.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
2
3
+0
6
Translate
Report
3515 Views
Comment
Sign in to post a comment
1907Followers
30Following
23KVisitors
Follow